Özgür Yaldizli1, Varun Sethi2, Matteo Pardini3, Carmen Tur4, Kin Y Mok5, Nils Muhlert6, Zheng Liu7, Rebecca S Samson2, Claudia A M Wheeler-Kingshott2, Tarek A Yousry8, Henry Houlden9, John Hardy9, David H Miller10, Declan T Chard10. 1. Queen Square MS Centre NMR Research Unit, Department of Neuroinflammation, UCL Institute of Neurology, London, UK; Department of Neurology, University Hospital Basel, Basel, Switzerland. Electronic address: o.yaldizli@ucl.ac.uk. 2. Queen Square MS Centre NMR Research Unit, Department of Neuroinflammation, UCL Institute of Neurology, London, UK. 3. Queen Square MS Centre NMR Research Unit, Department of Neuroinflammation, UCL Institute of Neurology, London, UK; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy. 4. Queen Square MS Centre NMR Research Unit, Department of Neuroinflammation, UCL Institute of Neurology, London, UK; MS Centre of Catalonia (Cemcat), Neurology-Neuroimmunology Department, Vall d'Hebron University Hospital, Barcelona, Spain. 5. Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; Division of Life Science, Hong Kong University of Science and Technology, Hong Kong SAR, China. 6. Queen Square MS Centre NMR Research Unit, Department of Neuroinflammation, UCL Institute of Neurology, London, UK; School of Psychology and Cardiff University Brain Research Imaging Centre, Cardiff University, Cardiff, UK; School of Psychological Sciences, University of Manchester, Manchester, UK. 7. Queen Square MS Centre NMR Research Unit, Department of Neuroinflammation, UCL Institute of Neurology, London, UK; Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China. 8. Queen Square MS Centre NMR Research Unit, Department of Neuroinflammation, UCL Institute of Neurology, London, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, UK; Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, UK. 9. Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK. 10. Queen Square MS Centre NMR Research Unit, Department of Neuroinflammation, UCL Institute of Neurology, London, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, UK.
Abstract
BACKGROUND: The HLA-DRB*1501 haplotype influences the risk of developing multiple sclerosis (MS), but it is not known how it affects grey matter pathology. AIM: To assess HLA-DRB(*)1501 effects on magnetic resonance imaging (MRI) cortical grey matter pathology. METHODS: Whole and lesional cortical grey matter volumes, lesional and normal-appearing grey matter magnetization transfer ratio were measured in 85 people with MS and 36 healthy control subjects. HLA-DRB(*)1501 haplotype was determined by genotyping (rs3135388). RESULTS: No significant differences were observed in MRI measures between the HLA-DRB(*)1501 subgroups. CONCLUSIONS: The HLA-DRB(*)1501 haplotype is not strongly associated with MRI-visible grey matter pathology.
BACKGROUND: The HLA-DRB*1501 haplotype influences the risk of developing multiple sclerosis (MS), but it is not known how it affects grey matter pathology. AIM: To assess HLA-DRB(*)1501 effects on magnetic resonance imaging (MRI) cortical grey matter pathology. METHODS: Whole and lesional cortical grey matter volumes, lesional and normal-appearing grey matter magnetization transfer ratio were measured in 85 people with MS and 36 healthy control subjects. HLA-DRB(*)1501 haplotype was determined by genotyping (rs3135388). RESULTS: No significant differences were observed in MRI measures between the HLA-DRB(*)1501 subgroups. CONCLUSIONS: The HLA-DRB(*)1501 haplotype is not strongly associated with MRI-visible grey matter pathology.
Authors: Lukas Simon Enz; Thomas Zeis; Daniela Schmid; Florian Geier; Franziska van der Meer; Guido Steiner; Ulrich Certa; Thomas Martin Christian Binder; Christine Stadelmann; Roland Martin; Nicole Schaeren-Wiemers Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-12-27